For 30 years, the Clinique médicale l’Actuel, under the medical direction of Dr. Réjean Thomas, has been bringing together healthcare professionals, with a focus in virology, to learn from guest experts and discuss the most relevant clinical practice challenges facing them today.
Residual Immune Dysregulation in the Age of New Antiretroviral Therapies
With Dr. Réjean Thomas and Dr. Daniel E. Kaufmann
After clicking PLAY, click on the lower bar’s subtitles icon [CC] for english subtitles.
- Ten to 15% of HIV patients experience significant immune dysregulation, despite efficacious ART.
- Risk factors for this complication: low CD4 count and inflammation.
- Significant impact: illnesses not traditionally linked to HIV, e.g. premature aging, reduced life expectancy.
This activity is supported
by an educational grant from:
Residual Immune Dysregulation in the Age of New ART
Certain HIV patients exhibit persistent immune dysregulation, despite efficacious antiretroviral treatment. Dr. Daniel Kaufmann devotes his research to this group of patients, focussing especially on understanding the immunology of the response in this group and the mechanisms that contribute to this phenomenon, which affects between 10 and 15% of PLHIV.
This suboptimal immune response is characterized by a relatively low CD4 count or signs of inflammation, and has a significant impact on affected patients. In addition, they are more exposed to complications not traditionally linked to HIV, e.g. premature cardiovascular disease, cancer, dementia or metabolic disorders such as diabetes. These complications are normally associated with aging, but in these patients, they occur especially early, and life expectancy is shorter than in other PLHIV.
According to Dr. Kaufmann, the research looks promising, but much remains to be done. While we wait for efficacious therapies, research is helping reduce the risks and the impact of these complications on the health of patients.
Réjean Thomas, MD, Dhc
CEO – Founder
Clinique médicale l’Actuel: Centre of Excellence HIV–STI–Hepatitis
Affiliated with the Centre hospitalier de l’Université de Montréal (CHUM)
Daniel E. Kaufmann, MD
Department of Microbiology, Infectious Diseases and Immunology
Faculty of Medicine
Université de Montréal
AND THE SUPPORT OF
ViroChannel has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Réjean Thomas, MD, Dhc has a financial interest/relationship or affiliation with:
Advisory Boards: AbbVie, Bristol-Myers Squibb Janssen, Gilead, Merck, ViiV Healthcare
Daniel E. Kaufmann, MD has a financial interest/relationship or affiliation with:
Disclosure of Unlabeled Use The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.